Rivas Medical Weight Loss

Rivas Medical Weight Loss operates a physician-supervised weight loss clinic in Bowie, Maryland, serving patients throughout Prince George's County and offering telehealth consultations to residents of Maryland, Virginia, and Florida. The practice centers its clinical approach on GLP-1 receptor agonist therapy, specifically utilizing semaglutide and tirzepatide as primary pharmaceutical interventions for patients with obesity and metabolic dysfunction. Dr. Rivas leads a clinical team that structures weight loss programs around weekly monitoring protocols, allowing for dose adjustments and metabolic response tracking throughout the treatment course. The clinic integrates metabolic testing to establish baseline measurements and lipotropic injection therapy as adjunctive support for patients on GLP-1 medications.

Semaglutide and tirzepatide represent the core peptide therapies at Rivas Medical Weight Loss, with dosing protocols individualized based on patient tolerance, weight loss velocity, and metabolic markers. Semaglutide functions as a GLP-1 receptor agonist that regulates appetite and glucose metabolism, while tirzepatide operates through dual GLP-1 and GIP receptor activation, offering an alternative mechanism for patients who require enhanced metabolic intervention. The clinical team develops individualized nutrition plans that complement the appetite-suppressing effects of these medications, addressing macronutrient distribution and caloric targets specific to each patient's metabolic testing results. Lipotropic injections containing compounds such as methionine, inositol, and choline are available as supplementary therapy to support hepatic fat metabolism during active weight loss phases.

Dr. Rivas oversees all treatment protocols and maintains direct involvement in patient care planning, with nurse practitioners conducting weekly monitoring visits that track weight changes, vital signs, and medication side effects. The clinical team's approach emphasizes education on GLP-1 therapy mechanisms, realistic weight loss timelines, and strategies for maintaining results after medication discontinuation. Patients receive guidance on managing common tirzepatide and semaglutide side effects including nausea, constipation, and appetite changes, with dose titration adjusted to minimize gastrointestinal symptoms while maintaining therapeutic effectiveness. The structured program format includes regular check-ins that allow the clinical staff to address patient questions and modify nutrition plans as weight loss progresses and metabolic needs shift.

Patients at the Bowie location can expect an initial consultation that includes comprehensive metabolic assessment, body composition analysis, and discussion of weight loss goals to determine candidacy for GLP-1 therapy. The front desk staff coordinates weekly appointment schedules and manages prior authorization processes for semaglutide and tirzepatide prescriptions, as insurance coverage varies significantly for weight loss indications. In-person visits at the Prince George's County clinic allow for direct measurement and clinical assessment, while telehealth options provide access for patients in Maryland, Virginia, and Florida who require ongoing monitoring but cannot travel to Bowie regularly. The clinical team maintains a protocol-driven approach to dose escalation, typically starting patients on lower doses of semaglutide or tirzepatide and increasing gradually over 12-20 weeks to minimize side effects and assess individual response.

Rivas Medical Weight Loss differentiates its service model through the combination of weekly monitoring frequency and integration of metabolic testing with GLP-1 therapy, providing a level of clinical oversight that exceeds standard prescription-only weight loss programs. The availability of both in-person care in Bowie and telehealth access across three states addresses the practical barriers many patients face in maintaining consistent follow-up during extended weight loss treatment courses. With a 4.9-star rating across 148 Google reviews, the clinic has established a patient base that values the structured approach and clinical team accessibility. The practice accepts patients seeking medically supervised weight loss who meet clinical criteria for GLP-1 therapy, including those with BMI thresholds that qualify for pharmacological intervention or patients with obesity-related comorbidities such as prediabetes or metabolic syndrome.